

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number  
**WO 2004/016261 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/198**,  
A61P 33/00

(81) Designated State (*national*): US.

(21) International Application Number:  
PCT/JP2002/008209

(84) Designated States (*regional*): European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE, SK, TR).

(22) International Filing Date: 12 August 2002 (12.08.2002)

**Declarations under Rule 4.17:**

(25) Filing Language: English

— *as to the identity of the inventor (Rule 4.17(i)) for all des-*  
*ignations*

(26) Publication Language: English

— *as to applicant's entitlement to apply for and be granted a*  
*patent (Rule 4.17(ii)) for all designations*

(71) Applicants and

— *as to applicant's entitlement to apply for and be granted a*  
*patent (Rule 4.17(ii)) for all designations*

(72) Inventors: MURAYAMA, Yuuichi [JP/JP]; 6-13-205,  
Matsushiro 3-chome, Tsukuba-shi, Ibaraki 305-0035  
(JP). MORIYAMA, Masami [JP/JP]; 13-20-311, Bessho  
1-chome, Minami-ku, Yokohama-shi, Kanagawa 232-0064  
(JP).

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *with international search report*  
— *with amended claims and statement*

(74) Agent: KUSAMA, Osamu; KUSAMA PATENT  
OFFICE, 7F, Iwata Bldg., 5-12, Iidabashi 4-chome, Chiy-  
oda-ku, Tokyo 102-0072 (JP).

*For two-letter codes and other abbreviations, refer to the "Guid-*  
*ance Notes on Codes and Abbreviations" appearing at the begin-*  
*ning of each regular issue of the PCT Gazette.*

(54) **Title:** METHOD FOR SUPPRESSING PROLIFERATION OF ABNORMAL PRION PROTEIN WITH LEUCINE,  
ISOLEUCINE OR VALINE

(57) **Abstract:** A method for suppressing proliferation of abnormal prion proteins is provided. Specifically, the method involves systemically, orally, intracerebrally or intraspinally administering an essential amino acid, in particular, one having a branched side chain, that is, one selected from leucine, isoleucine, and valine. Of these, leucine is most preferred.



WO 2004/016261 A1